Edgen AI operates independently of, and is not controlled by Aspen Digital Financial Limited.
Analog chip stocks rebound as cycle turns on 3-year high bookings
Edgen Stock·Jul 12 2026, 12:27Share to
Share to
Copy link
[1] 5 Analog Chip Stocks Set to Rebound as the Cycle Changes (https://247wallst.com/investing/2026/07/12/5- ...)[2] My Updated 2026 Market Outlook: Keeping The S&P 500 Target, But Changing Sector Leaders (https://seekingalpha.com/article/4921209-my-u ...)[3] Can SanDisk Outperform the Semiconductor Sector in 2026? (https://247wallst.com/investing/2026/07/08/ca ...)[4] Why The iShares Semiconductor ETF Soared 112.8% In The First Half of 2026 (https://www.msn.com/en-us/money/savingandinve ...)
Related News
Jul 31 2026, 20:25
Vericel swings to profit on $77.5 million Q2 revenue beat
Vericel reported Q2 revenue of $77.5 million, beating consensus by about $3.3 million, and swung to a profit of $0.04 a share. | Metric | Actual | Consensus | Beat/Miss | |--------|--------|-----------|-----------| | Revenue | $77.5M | $74.1M | +4.5% | | EPS | $0.04 | -$0.03 | +$0.07 | The Cambridge, Massachusetts-based cell therapy company posted earnings per share of $0.04 for the quarter ended June 30, versus a consensus estimate of a $0.0287 loss. Revenue of $77.46 million topped the $74.14 million analysts expected, a beat of roughly 4.5 percent. Vericel, which markets MACI for knee cartilage repair, Epicel for severe burns and NexoBrid for burn debridement, reported the results on July 30. The company trades on the Nasdaq under the ticker VCEL. The beat extends Vericel's run of topping Wall Street estimates as demand for its cell therapy products holds up. The company has built its franchise around MACI, its flagship autologous chondrocyte implant, alongside the burn-care products Epicel and NexoBrid. The swing to profitability shows the strength of Vericel's cell therapy franchise. Investors will watch the company's earnings call for updated full-year guidance and any signal on MACI procedure growth into the second half of 2026. This article is for informational purposes only and does not constitute investment advice.
Jul 31 2026, 20:12
Butterfly Network beats Q2 estimates on $32.6M revenue, narrower EPS loss
Butterfly Network reported Q2 revenue of $32.6 million, beating consensus of $29.9 million, with EPS loss narrowing to $0.01. The company's handheld ultrasound platform continues to gain traction in point-of-care settings, with revenue exceeding analyst projections by $2.7 million. The company did not disclose forward guidance in its earnings release. | Metric | Actual | Consensus | Beat/Miss | |--------|--------|-----------|-----------| | Revenue | $32.6M | $29.9M | +8.9% | | EPS | -$0.01 | -$0.0587 | +$0.0487 | Revenue of $32.6 million came in 8.9 percent above the $29.9 million consensus. The EPS loss of $0.01 compared with the $0.0587 loss analysts had projected, a $0.0487 per-share improvement. The results mark continued progress toward profitability as the company scales its portable ultrasound devices against larger competitors including GE HealthCare and Philips. Butterfly Network, which trades on the NYSE under the ticker BFLY, has built its business around a single-probe, whole-body ultrasound system designed for use across emergency departments, primary care, and remote settings. The company's Q2 performance reflects sustained demand for its handheld devices, though year-over-year revenue comparisons were not disclosed in the release. The beat comes as the broader medical imaging market continues to shift toward portable and accessible diagnostic tools. Traditional ultrasound leaders GE HealthCare and Philips have expanded their own handheld offerings, intensifying competition in the point-of-care segment. Butterfly's ability to exceed consensus estimates suggests its software-enabled approach and subscription-based business model are resonating with clinical customers. The narrower loss signals improving operating leverage for the medical device maker. Investors will watch the company's earnings call for updated guidance and any commentary on adoption trends across its clinical customer base. This article is for informational purposes only and does not constitute investment advice.
Jul 31 2026, 20:07
Farmer Mac beats Q2 estimates with $5.40 EPS on $125M revenue
Farmer Mac reported Q2 EPS of $5.40, beating the $4.92 consensus by 10 percent, with revenue of $125.2 million topping estimates. The Federal Agricultural Mortgage Corp., known as Farmer Mac, released results July 30 for the quarter ended June 30. The government-sponsored enterprise trades on the New York Stock Exchange under the ticker AGM. The company's earnings release did not include management commentary or updated guidance. Revenue of $125.2 million exceeded the $114.6 million consensus by $10.6 million, a 9.2 percent beat. EPS of $5.40 came in $0.48 above the $4.92 estimate. Year-over-year comparisons and segment-level breakdowns were not disclosed in the release. The beat extends Farmer Mac's pattern of exceeding consensus estimates, reflecting continued demand for agricultural credit. Investors will watch for updated credit metrics and portfolio growth when the company discusses results on its earnings call. | Metric | Actual | Consensus | Beat/Miss | |--------|--------|-----------|-----------| | Revenue | $125.2M | $114.6M | +9.2% | | EPS | $5.40 | $4.92 | +$0.48 | Farmer Mac operates as a secondary market for agricultural real estate and rural housing loans, providing liquidity to agricultural lenders across the United States. The company was chartered by Congress in 1988 and functions as a government-sponsored enterprise, similar in structure to Fannie Mae and Freddie Mac but focused exclusively on the agricultural sector. The Q2 performance positions Farmer Mac alongside housing-focused GSEs Fannie Mae and Freddie Mac, which serve as the closest structural peers in the government-sponsored enterprise space. Farmer Mac's narrower mandate in agricultural lending differentiates its credit profile from those housing-focused entities, with its loan portfolio concentrated in farm real estate mortgages, rural housing loans, and agricultural operating credit. The company's results come as farm credit conditions remain a focus for investors tracking the broader agricultural economy. Agricultural land values and farm income trends have been closely watched by market participants, given their direct impact on the credit quality of Farmer Mac's loan portfolio. Forward guidance for the remainder of fiscal 2026 was not yet disclosed. The company's next scheduled earnings release would cover Q3 results. The earnings beat points to continued strength in the agricultural lending market, where Farmer Mac provides a critical secondary market function. Investors will look to the company's next quarterly report for updated loan portfolio growth and credit quality metrics, along with any changes to its dividend policy. This article is for informational purposes only and does not constitute investment advice.